NEWSRELEASE



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.

Several important developments have taken place over the last few months both for FAD, with regards to the MucoAd technology, and for Delmedica with its Asthma device.

The developments for Delmedica are listed below:

- Delmedica attended the World Allergy Organisation (WAO) conference in Bangkok where we had a hospitality suite allowing us to discuss the advances in our technologies in a relaxed manner.
- The international PCT patent application for the device has now entered its national phase and we have submitted the patent initially to the national patent offices for the US, Europe and Japan.
- Prof.Kostianev, is currently working to make a thorough assessment of the EBT device in terms of age, gender, smoker status, food and hormonal influence.
- Dr Vicheva and Dr. Aleksieva are investigating the relationship between the onset of tuberculosis and or pneumonia in children and changes in EBT.
- Dr.Diana Dumitrascu will look at the effect of circadian rhythms on EBT
- Prof. N.Papadopoloulos has started a clinical study on 100 children looking at changes in airway inflammation during virus-induced acute asthma exacerbations that might be reflected in changes in EBT. The aim of the study is to evaluate the EBT during virologically confirmed acute exacerbations in asthmatic children in comparison to the EBT of asthmatic children outside an exacerbation. This study should also allow us to ascertain whether the device can discriminate between different viruses.
- Initial clinical work by Dr.Davchev has shown that in patients with active lung tuberculosis proven on the basis of bacilli in sputum, measurements demonstrated correlation between gold standard clinical criteria for active disease and exhaled breath temperature (EBT).
  - Morning axillary temperature was below 36°C in all subjects
  - EBT in 2 patients was > 36°C
  - None of the patients had EBT < 35.3°C
  - Decrease of EBT by 1.0 - 1.5°C after 2-3 weeks of treatment
- Dr.Davchev will continue the studies with patients with COPD and pneumonia, after he has completed his study with patients with tuberculosis.
- An abstract has been written comparing the EBT device with peek flow meter measurements entitled " Ability of an Individual device for measurement of the temperature of exhaled breath to detect changes in patients recovering from mild exacerbations of asthma". This paper will be submitted to the European Respiratory Society (ERS) meeting in Berlin in October 2008
- An agreement has been signed between Delmedica Investments (Singapore) Ltd and Philips Electronics to redesign the device to add electronics and ergonomics and to produce 2000 pieces which will be used to further define and elaborate the advantages of the device in various product/market combinations.

FAD have also booked some important advances further proving the competitive advantage of the technology;

- The abstract for the fluorescein and saccharine study comparing MucoAd with standard carriers for nasal applications has been approved for the AAAAI conference in Philadelphia in March 2008
- The abstract for the fluorescein study comparing MucoAd with standard carriers for ocular applications has been approved for the AAAAI conference in Philadelphia in March 2008
- An initial study comparing various delivery systems for MucoAd (measurement pipette, dropper and a spray device) has shown that spray devices are an effective delivery system for this technology and no negative impact was seen either on its efficacy or patients perception.
- Recent customer contacts have shown interest from both Alcon and Wyeth.